Adimab Forms Discovery Collaborations with Biogen & Novo Nordisk for Antibodies

Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales.

Antibody discovery and optimization platform provider Adimab has signed separate discovery agreements with Biogen Idec and Novo Nordisk for antibodies development.

Adimab will use its platform to identify fully human antibodies against two targets selected by Biogen and two from Novo Nordisk. Both Biogen and Novo Nordisk have the option to commercialize antibodies generated from the collaborations.

Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales.

Tillman Gerngross, Adimab’s chief executive officer and co-founder, said, “Our pa